BlackRock, Inc. 13D and 13G filings for Nektar Therapeutics:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
2025-04-17 09:35 am Sale |
2025-03-31 | 13G | Nektar Therapeutics NKTR |
BlackRock Inc. BLK |
835,200 6.700% |
-229,423![]() (-21.55%) |
Filing |
2024-11-08 5:31 pm Unchanged |
2024-09-30 | 13G | Nektar Therapeutics NKTR |
BlackRock Inc. BLK |
1,064,623 8.700% |
0 (Unchanged) |
Filing |
2024-10-22 3:24 pm Purchase |
2024-09-30 | 13G | Nektar Therapeutics NKTR |
BlackRock Inc. BLK |
1,064,623 8.700% |
491,002![]() (+85.60%) |
Filing |
2023-07-07 4:35 pm Sale |
2023-06-30 | 13G | Nektar Therapeutics NKTR |
BlackRock Inc. BLK |
573,621 4.500% |
-646,423![]() (-52.98%) |
Filing |
2023-05-05 11:52 am Sale |
2023-04-30 | 13G | Nektar Therapeutics NKTR |
BlackRock Inc. BLK |
1,220,045 9.700% |
-1,175,161![]() (-49.06%) |
Filing |
2023-01-23 3:52 pm Purchase |
2022-12-31 | 13G | Nektar Therapeutics NKTR |
BlackRock Inc. BLK |
2,395,206 19.100% |
617,086![]() (+34.70%) |
Filing |
2022-01-27 1:59 pm Unchanged |
2021-12-31 | 13G | Nektar Therapeutics NKTR |
BlackRock Inc. BLK |
1,778,120 14.500% |
0 (Unchanged) |
Filing |
2022-01-25 6:45 pm Purchase |
2021-12-31 | 13G | Nektar Therapeutics NKTR |
BlackRock Inc. BLK |
1,778,120 14.500% |
552,915![]() (+45.13%) |
Filing |
2021-01-26 6:52 pm Sale |
2020-12-31 | 13G | Nektar Therapeutics NKTR |
BlackRock Inc. BLK |
1,225,205 10.200% |
-2,630![]() (-0.21%) |
Filing |